FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00606528|
Recruitment Status : Completed
First Posted : February 4, 2008
Last Update Posted : July 25, 2013
|Condition or disease||Intervention/treatment|
|Chronic Hepatitis C Virus Infection||Other: No intervention|
The current therapy for chronic Hepatitis C Virus infection leads to a sustained viral response in only 50% of treated patients. Evidence suggests that a poor response to treatment may be the result of a dysfunction of immunoregulatory mediators including T regulatory cells (Tregs) which secrete FGL2. The aim of this study is to test whether serum FGL2 levels can serve as a biomarker for clinical progress and treatment response in patients undergoing anti-viral therapy for chronic HCV infection.
This study will measure the blood Treg and FGL2 levels of patients with chronic Hepatitis C as they undergo antiviral therapy and will compare those levels to their pre-treatment and post-treatment levels. Treg and FGL2 expression levels will also be measured in patients' liver biopsy tissue when available.
Additionally, this study will examine the main form(s)of Fc Receptor expressed in these patients. The Fc receptor is the hypothesized binding partner of FGL2, and the form expressed in a given patient may determine the downstream effects of FGL2's binding. These data along with clinical, biochemical and virological data will be used to determine whether there is a correlation between FGL2 levels and disease outcome and/or treatment response.
The study will also recruit a group of normal healthy volunteers to give blood samples on two occasions so that the baseline range of FGL2 levels in healthy individuals can be established for comparison.
|Study Type :||Observational|
|Actual Enrollment :||54 participants|
|Official Title:||FGL2/Fibroleukin and Hepatitis C Virus Infection: A Predictor of Response to Antiviral Therapy|
|Study Start Date :||February 2008|
|Actual Primary Completion Date :||July 2013|
patients with chronic Hepatitis C Virus infection who have not previously received antiviral therapy
Other: No intervention
None. This is an observational study.
Healthy volunteers willing to donate blood on 2 separate occasions
- correlation between blood FGL2 levels and response to antiviral therapy [ Time Frame: 6 months after the end of treatment ]
- correlation between FGL2 levels and Treg percentage in blood and liver cells [ Time Frame: all time points ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00606528
|University Health Network|
|Toronto, Ontario, Canada, M5G 2C4|
|Principal Investigator:||Gary Levy, MD||University Health Network, Toronto|